National Taiwan University Hospital (NTUH)

GenomeFrontier is conducting a Phase 1 clinical trial (NCT06703892) at  National Taiwan University Hospital (NTUH) to evaluate the safety and preliminary clinical activity of our first-in-class, non-viral autologous CAR T cell therapy, GF-CART01, in patients with B cell malignancies.